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ABSTRACT 
 
 
Abdominal aortic aneurysms (AAA) are an area of dilation in the vessel that is 
greater than 3.0 cm in diameter or an area of the vessel that enlarged to greater than 50% 
of the vessel’s original diameter1,2,3. AAA are generally asymptomatic and if ruptured, have 
a mortality rate of 78-83%4. AAA account for approximately 45,000 surgeries performed 
in the United States annually and are the 13th leading cause of death in the United States1,2. 
Alterations of two extracellular matrix proteins, elastin and collagen, are associated with 
the formation of abdominal aortic aneurysms5. AAA formation is marked by degradation 
of elastin and collagen induced by matrix metalloproteinases (MMPs) as well as a decrease 
in the amount of smooth muscle cells in the artery4,5. 
 Elastase is the standard method of inducing an aneurysm in arterial tissue by 
breaking down the elastin fibers in the extracellular matrix. Numerous in vivo models have 
been published to induce the formation of an aneurysm using elastase, however there has 
yet to be model optimized in an ex vivo environment showing progressive AAA 
formation6,7. An optimal ex vivo model is advantageous in the hopes of advancing 
aneurysmal research by studying abdominal aortic aneurysms through organ culture. This 
optimal ex vivo model should be consistent with previous in vivo models; diminished 
elastin content and smooth muscle cells and show presence of MMPs. Additionally, this 
model should minimize death of native cells in order to recapitulate an in vivo response 
and investigate the relationship between elastin damage and calcification. Therefore, our 
lab aims to produce an ex vivo model of elastase-induced elastin degradation in porcine 
carotid arteries that minimizes death of native cells. 
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1 
CHAPTER ONE 
INTRODUCTION 
  
Cardiovascular diseases (CVD) are the leading cause of death in the United States8,9. 
CVD are responsible for 1 out of every 4 deaths in the United States, accounting for over 
610,000 deaths per year. Aortic aneurysms accounted for nearly 10,000 deaths in the 
United States in 2014 and contributed to over 17,000 deaths in 20099,10,11. In studying 
potential therapies for these CVD and understanding disease pathology and mechanisms, 
we must first understand the anatomy and physiology. 
 
1.1 Arterial System Anatomy and Physiology 
 
 The cardiovascular system is a complex system in living organisms consisting of 
the heart, blood vessels, and blood. The blood vessels of the cardiovascular system consist 
of arteries, arterioles, capillaries, venules, and veins12. The direction of blood flow is as 
follows: from arteries, to arterioles, to capillaries, to venules, and then to veins (Figure 1.1). 
Most blood vessels consist of three tunics: the tunica intima (innermost), tunica media 
(middle), and tunica adventitia (outer) (Figure 1.1)13. These three tunics are all composed 
of smooth muscle cells and varying amounts of collagen and elastin. The cellular makeup 
of these different tunics is determined based on the blood vessel’s function in the body12. 
 2 
12 
 
Figure 1.1: Direction of blood flow through the blood vessels and the three tunics of 
blood vessels12. 
 
 The tunica intima is connected to a basement membrane and is composed of one 
layer of endothelial cells12. Endothelial cells aid in homeostatic functions of vascular 
tissues, and play a role in both inflammatory and immune responses. The internal elastic 
lamina that is below the basement membrane aids the endothelial cells of the tunica intima 
by providing flexibility and stability to these cells. In addition to endothelial cells, another 
cell type, pericytes, are also found in the tunica intima. Pericytes are believed to have 
numerous functions, as they are capable of differentiating into a wide range of different 
cell types, like fibroblasts and vascular smooth muscle cells (VSMCs)14. Additionally, 
pericytes aid in contraction of the blood vessel14. The middle tunic, the tunica media is 
composed of elastin fibers and smooth muscle cells12. In larger arteries, the cells of the 
tunica media are highly organized, due to their function in contractibility of the vessel 
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required for the movement of large quantities of blood. The internal and external elastic 
lamina of the tunica media imparts structural support to this tunic and separates it from the 
intima and adventitia respectively. The outermost tunic, the tunica adventitia is nearly 
completely composed of connective tissue that is fibro-elastic in nature12. The tunica 
adventitia provides mechanical support as well as houses the vasa vasorum, a network of 
small blood vessels, to provide nutrients to the vessel wall cells. 
 Arteries can be classified as being either elastic or muscular12. Found nearest the 
heart, elastic (conducting) arteries aid in the movement of large quantities of blood and 
have many layers of elastin, an extracellular matrix (ECM) component that gives blood 
vessels elasticity. These elastic arteries aid the muscular (distributing) arteries in creating 
blood flow that is more homogenized by working to dampen the large oscillations of blood 
flow. Muscular arteries are more muscular in composition. These arteries are shown to 
have numerous smooth muscle cells along with elastin fibers that are discontinuous in 
nature12.  
Arteries bifurcate, becoming smaller, and become arterioles, working to diminish 
the flow of blood from larger arteries in order to prevent capillary damage further down-
stream12. Capillaries connect the arterial and venous systems. Capillaries lack smooth 
muscle cells and are composed of a single layer of endothelial cells, pericytes, and a 
basement membrane. Nutrient and solute exchange occurs at the capillary bed via 
hydrostatic and osmotic pressures. From the capillaries, blood will flow through the 
venules, which come together to form veins in order to return blood to the heart12.  
 
 4 
1.2 Aorta Anatomy and Physiology 
 
The aorta is the largest blood vessel in the body, carrying oxygenated blood to the 
body from the left ventricle via the aortic valve and is broken down into the thoracic and 
abdominal aorta15. The thoracic aorta involves the ascending aorta, aortic arch, and 
descending aorta. The aortic arch branches into the left subclavian artery, left common 
carotid artery, and innominate artery, which further bifurcates into the right common 
carotid artery and the right subclavian artery. After the descending thoracic aorta, the 
abdominal aorta emerges as it passes under the aortic hiatus of the diaphragm and ends as 
it branches into the right and left iliac arteries, usually 2-3 cm below the umbilicus (Figure 
1.2)16.  
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Figure 1.2: Anatomy of the aorta17.  
 
1.3 The Extracellular Matrix 
 
The extracellular matrix (ECM) is a highly dynamic structure that is  principally 
composed of polysaccharides, proteins, and water  and is important in providing strength 
and stability to tissues, as well as being involved in cell adhesion, signaling, and 
differentiation18,19.  The principle proteins of the ECM include proteoglycans and fibrous 
proteins, including collagens, elastin, and fibronectins. 
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1.3.1 Proteoglycans 
Proteoglycans have glycosaminoglycan (GAG) chains that are linked by covalent 
bonds to a core protein20. Proteoglycans are found in the extracellular interstitial space of 
the tissue and have important functions in buffering, hydration, binding, and force-
resistance19. GAGs are polymer chains that are linear and unbranched, consisting of 
repeating disaccharides that are composed of a hexosamine and a uronic acid21. GAGs have 
a negative charge, attracting Na+, resulting in water migrating into the interstitial space of 
the ECM and causing the GAGs to swell as a result of the influx of water21. Thus, GAGs 
provide tissue hydration and compressive strength to the tissue. 
 
1.3.2 Collagen 
Of all the fibrous proteins in the ECM, collagen is the most abundant, forming one-
third of the total protein in humans21,22. Collagen is a right-handed triple-helix held together 
by hydrogen bonds that are composed of XaaYaaGly resides, where the third residue must 
be Gly and Xaa and Yaa can be any amino acid22. (2S)-proline and 4-hydroxyproline are 
the amino acids most found in the Xaa and Yaa positions, respectively.  Collagens serve 
important roles in cell adhesion, chemotaxis and cell migration, tissue development, and in 
providing tensile strength to the tissue. Collagen fibrils are formed by self-assembly23. Due 
to its ability to self-assemble and crosslink, collagen is important in providing strength and 
stability to the ECM24. Collagen is both transcribed and secreted by fibroblasts. The 
fibroblasts influence the alignment of collagen fibers, as these cells are able to organize 
collagen fibers into sheets19. There have been over 16 different types of collagen identified 
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all coming from a single ancestral gene25,26. Of these 16 different types, 80-90% of these 
belong to collagen types I, II, and III26.  
Type I collagen is the most abundant collagen in the body and is found in skin, 
tendon, bone, ligaments, dentin, and interstitial tissues26. Type II is found in the cartilage 
and vitreous humor. Type III is found in the skin, muscle, blood and blood vessels. Type I 
collagen has the form [a1(I)]2a2, as it is composed of two a1-type I chains and one a2-
chain, while types II and III have the forms [a1(II)]3 and [a1(III)]3, respectively, having 
three a1-type II chains and three a1-type III chains27. Type III collagen has been shown to 
be of great importance in maintaining the structural integrity of the blood vessels28. Though 
the association of type III collagen and blood vessels has been established, the molecular 
function of type III collagen in this regard is still largely unknown28.  
 
1.3.3 Elastin 
Elastin fibers are important in providing recoil to tissues that are stretched 
repeatedly, examples being skin, lungs, blood vessels, and elastic cartilage. These elastin 
fibers are composed of elastin and microfibrils29. 90% of the composition of elastic fibers 
is elastin that is surrounded by microfibrils that are composed of numerous glycoproteins 
such as fibrillin and fibulins30. Elastin has minimal polar groups and numerous 
hydrophobic amino acid residues. Elastin is derived from its precursor, tropoelastin, and is 
highly cross-linked by lysine residues due to the action of lysyl oxidase enzymes that 
makes elastin an insoluble protein17,31,32.  Lysyl oxidase cross-links elastin via the 
conversion of amine side chains in lysine residues to aldehydes33. Two additional amino 
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acid cross-linking residues of elastin are desmosine and isodesmosine, which are specific 
only for elastin and eggshell protein33,34. The ability of elastin to stretch is dictated by its 
association with collagen fibers19. Elastin can be degraded by proteases with elastase 
activity3. Figure 1.3 depicts the process of elastin formation and crosslinking, as derived 
from its precursor tropoelastin, and its degradation by the elastase enzyme35. 
 
Figure 1.3: Mechanism of elastin formation from tropoelastin and degradation by 
elastase35. 
 
The structure and organization of elastin fibers varies throughout different tissues. 
These differences in are depicted in Figure 1.4.  In arteries, elastic fibers are organized into 
rings within the lumen of the artery. In lung tissue, the organization of elastin fibers is 
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concentrated in areas of the organ like the alveoli that are exposed to high stress. When 
observed in elastic cartilage, the elastin fibers are found in a honeycomb like 
organization30. 
 
Figure 1.4: Elastin fiber organization in arteries (a), lungs (b), and elastic cartilage 
(c)30. 
 
1.3.4 Fibronectin 
Fibronectin has important roles in ECM organization as well as in cell attachment 
and cell function. Fibronectin is a dimeric protein consisting of greater that 50 repeating 
subunits36. Fibronectin is an important mechanical regulator of the ECM, as this ECM 
protein can be stretched beyond its initial length, exposing integrin-binding sites which 
allow fibronectin to have roles in both scaffolding and cell recognition36. This ECM protein 
is implicated in the response to tissue injury, aiding in the formation of granulation tissue 
in the wound healing process37.  
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1.4 Abdominal Aortic Aneurysm 
 
1.4.1 Overview 
Abdominal aortic aneurysms (AAA) are caused by expansion in the infrarenal 
portion of the aorta that leads to weakening of the arterial wall (Figure 1.5). This ballooning 
of the wall, caused by degeneration of the ECM components elastin and collagen can lead 
to ultimate rupture of the wall, causing significant blood loss that is fatal if not treated 
quickly. Clinically, AAA are characterized as an area of dilation in the vessel that is greater 
than 3.0 cm in diameter or an area of the vessel that is enlarged to greater than 50% of the 
vessel’s original diameter1,2,3. A healthy infrarenal portion of the aorta has a diameter of 
15-24 mm. In the event of AAA rupture, the mortality rate is 78-83%38.  The prevalence of 
AAA is between 1.7-12.7% and AAA are currently the 13th leading cause of death in the 
United States3,38.  AAA are typically asymptomatic, as around 75% of patients have no 
symptoms and are diagnosed through imaging performed for other health issues39. In 
patients that do experience symptoms, these symptoms are often relatively vague, including 
complaints of back and abdominal pain3. 
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Figure 1.5: Abdominal aortic aneurysm40. 
 
1.4.2 Risk Factors 
 There are several risk factors associated with AAA. Caucasian men over age 60 are 
those that have the highest risk of having AAA, as 5-10% of men over the age of 65 will 
be diagnosed with AAA3,39.  The cause of this gender disparity still remains largely 
unknown41. Elastase induced AAA models in rodents have shown a marked increase in 
male rodents (82%) forming AAA over females (29%). The male rodents showed an 
increase in the presence of MMP-9 secreting macrophages within the aorta41.  
Smoking is considered the risk factor with the strongest connection to the 
development of AAA. Years smoking is directly related to the risk of developing AAA; 
those who have an extensive history of smoking are more likely to develop a AAA than 
those with a less lengthy smoking history. Additionally, current smokers have a higher rate 
of expansion of their AAA compared to non-smokers; 2.83 mm growth annually in current 
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smokers and 2.53 mm growth annually in non-smokers. Though the association with 
smoking and increased risk of AAA formation has been discovered, the mechanism 
between the two has yet to be discovered.  
Atherosclerosis is also a commonly associated risk factor with AAA. It is believed 
that the ECM remodels in response to shear stress alterations due to arterial stenosis, as 
elastin fibers in the ECM break due to the influx of inflammatory cells associated with 
stenosis42. Coronary artery disease is also a risk factor associated with AAA, as 40-60% of 
patients with AAA also have coronary artery disease, however the mechanisms associating 
the two conditions are still largely unknown3,43.  
  Family history is also an important risk factor in AAA formation. Those that have 
a family history of AAA have a four-fold increase in the potential for AAA formation3. 
Additionally, those with a family history of AAA that do develop a AAA have a higher 
risk of AAA rupture earlier in life than those with no AAA family history3. Genome-wide 
scans of families with at least 2 family members with AAA have shown the possibility of 
a genetic cause of AAA, specifically associated with genes on chromosome 19q13 and 
4q3144. Possible genes in these chromosomal regions include interleukin 15, endothelin 
receptor A, programmed cell death 5, and LDL receptor-related protein 344. Replication of 
these gene studies have yielded inconsistent results. Several additional studies have also 
looked into the relationship of the C677 variant of the methylenetetrahydrofolate reductase 
gene as a possible genetic cause of AAA, however these have yielded inconsistent results 
as well45,46,47,48. 
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1.4.3 Pathophysiology of AAA 
 AAA are marked by inflammation and increased production of proinflammatory 
cytokines, production of matrix-degrading proteinases, destruction of elastin and collagen 
in the ECM, diminished presence of vascular smooth muscle cells (VSMCs), and oxidative 
stress as depicted in Figure 1.649,50. The mechanisms regarding the formation of AAA are 
still largely unknown, however the aforementioned markers can be used to confirm the 
presence of AAA histologically. 
 
 
 
Figure 1.6: Pathogenesis of AAA49. 
 
  
Alteration of elastin and collagen in the ECM are strong markers to confirm the 
presence of AAA. Alteration of these ECM components is caused by the production of 
proteases by resident vascular cells like VSMCs, fibroblasts, and infiltrating inflammatory 
cells3. Matrix metalloproteinases (MMPs) are important in remodeling of the ECM and are 
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particularly involved in the turnover of both elastin and collagen51. MMPs all share a 
catalytic site that is zinc dependent, require Ca2+, and are secreted by a latent proenzyme 
form. The primary activation of proteolytic enzymes is proceeded by cleavage of the 
propeptide by autocatylatic activation52. Two specific MMPs, MMP-2 and MMP-9 are 
implicated in the degradation of collagen and elastin, along with other substances and are 
associated with an inflammatory response caused by the invasion of macrophages51,53. 
MMP-2 (gelatinase A) is a 72 kDa protein produced from VSMCs located in the tunica 
media and tunica intima and from fibroblasts in the tunica adventitia. MMP-2 binding 
within the matrix is increased with the presence of AAA52,53. MMP-9 (gelatinase B) is a 92 
kDa protein and is more abundant than MMP-2, as it is found in high levels in AAA due 
to its secretion by inflammatory cells, including neutrophils, macrophages, and 
macrophage-derived osteoclasts52. Elastin degradation due to MMPs is also associated with 
the onset of vascular calcification, however the mechanism remains unknown54. 
 The diminished presence of VSMCs are thought to have implications in the 
capacity for repair of the ECM during this pathological process, further aiding in the 
formation of AAA50. VSMCs have roles in matrix synthesis, recruitment of inflammatory 
cells, and controlling proteases55. VSMC apoptosis has also been thought to initiate 
vascular calcification, as apoptotic blebs are able to collect calcium in a crystalized form56. 
Furthermore, these cells are elastolytic in AAA and believed to either have an acquired or 
innate phenotype that assists in degradation of the aorta due to the failure of a post-
transcriptional control factor associated with MMP-9 synthesis, which increases the 
amount of MMP-9 activation in AAA55.  
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 Additionally, other enzymes including cathepsins have been implicated in 
degradation of collagen and elastin and associated with AAA57. Cathepsins are cysteine 
proteases regulated by pro-inflammatory stimuli. Cathepsin S is a potent elastase and 
cathepsin K is a potent collagenase, while cathepsin L has elastin and collagen degradation 
properties similar to cathepsin S and cathepsin K. Research has found that VSMCs within 
the tunica intima can create cathepsins S and K during AAA formation, suggesting that 
cathepsins play a role in ECM remodeling58. Cathepsins S, K, and L are expressed by 
macrophages and play a role in arterial wall rupture57.  
 
1.4.4 Current Treatments 
 Current treatment of AAA is determined based on the risk of rupture, procedure 
risk, and estimated life expectancy of the patient,2,3. Currently, the size of the aneurysm is 
related to rupture risk, so patients with larger aneurysms are recommended for surgical 
treatment and those with aneurysms smaller than 5.5 cm are monitored by their physician 
as a more conservative approach without immediate surgical intervention, as studies have 
shown no benefit of early intervention for smaller aneurysms59. It is important to note that 
the rate of expansion of AAA after diagnosis is not related to the initial size of the 
aneurysm, so many believe that there are other factors associated with rate of expansion of 
the aneurysm.  
 Currently, there are two surgical options, open repair and endovascular repair which 
are depicted in Figure 1.7. During an open repair, a large incision is made from the distal 
aspect of the sternum, extending to the naval60. The aorta is exposed and the affected area 
 16 
is clamped to stop blood flow. The aneurysm is located and a fabric graft is stitched into 
place, rerouting blood through the graft rather than through the weakened artery. The artery 
is then sutured closed. An endovascular repair is a minimally invasive surgical technique. 
During this procedure, a graft is guided to the aneurysmal potion of the artery using a 
catheter via the femoral artery, rerouting the blood flow through the graft rather than the 
weakened vessel wall60. 
 
 
Figure 1.7: Comparison of an open AAA repair versus an endovascular AAA repair61. 
  
Studies have shown a diminished mortality rate within the first 30 days following 
surgery in an endovascular repair over an open repair; 1.6% versus 4.7%, respectively59. 
Despite the initial post-operative success, endovascular repairs are associated with 
increased post-operative complications and the need for reintervention later on. 
Additionally, there is no difference in quality of life after 3 months compared to an open 
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repair and there is no increase in survival compared to an open repair after 2 years59. The 
increased economic burden of an endovascular approach due to increased complications 
requiring possible reintervention and additional hospital stay, along with no significant 
differences in long term mortality and quality of life over time makes open repair the 
current gold standard for surgical repair of AAA. 
 
1.5 Modeling AAA 
 
Research continues to determine less invasive treatments for the prevention and 
treatment of AAA and further elucidate the mechanism of AAA formation62. 
 
1.5.1 In vitro Studies 
Various groups have used cell culture methods to look for future methods to reverse 
elastin damage. Previous work from Kothapalli, et. al has shown the roles of hyaluronan 
(HA), transforming growth factor-ß1 (TGF- ß1), and insulin-like growth factor in 
elastogenesis and the how the coupling of HA and TGF- ß1 has shown increased VSMC 
proliferation and elastin synthesis and stability in healthy VSMCs63,64,65. This group looked 
into the roles of HA and TGF- ß1 in VSMCs extracted from diseased AAA tissues from 
rats 4 weeks after a periadvential application of calcium chloride to induce an aneurysm. 
They found that using HA and TGF- ß1 in concert were most effective, as there was 
significantly higher elastin synthesis through upregulation of lysyl oxidase and 
desmosine66. 
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Additional work has been conducted to determine the possibility of the use of HA 
and TGF- ß1 to increase the elastogenic properties of VSMCs in late-stage AAA, where 
the VSMCs are unable to remodel damaged elastic fibers67. Aneurysmal rat SMCs 
(EaRASMCs) were harvested from adult male Sprangue Dawely rats 14 days after they 
underwent surgery to induce AAA formation via elastase perfusion. Supplementing HA 
and TGF- ß1in culture was shown to attenuate proliferation of EaRASMCs and increase 
synthesis of tropoelastin, while improving elastic fiber synthesis compared to healthy rat 
aortic SMCs (RASMCs). Additionally, supplementing HA and TGF- ß1 was found to 
restore the gene expression levels associated with EaRASMCs to mimic those associated 
with RASMCs. This study showed that it is possible to increase the elastogenic properties 
of SMCs in late-stage AAA via HA and TGF- ß1. One of the shortcoming of this approach 
was that there was no inhibition of MMP activity despite the incorporation of HA and TGF- 
ß1, thus newly formed elastin can further degrade and cause AAA67. 
  Swaminathan et. al recently published their findings targeted at combating 
continued AAA growth by and reversing elastolysis68. This was done by optimizing the 
conditions for in situ regeneration of elastin using smooth muscle cells derived from rat 
bone marrow (BM-SMCs). Prior to this study, the same group had shown that BM-SMCs 
in high glucose conditions showed improved elastin fiber formation and reduced the 
presence of MMPs when compared to aneurysmal rat SMCs, predicating the need to further 
investigate the effects of phenotypic differences in BM-SMCs impact synthesis of the 
elastin matrix69. The group found that there was an intermediate SMC phenotype associated 
BM-SMCs in a low glucose environment supplemented with TGF- ß1 and platelet-derived 
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growth factor (PDGF-BB) that possessed increased tropoelastin and elastin matrix 
synthesis compared to controls68. 
 Another group investigated the ways to mitigate high mobility group box 1 
(HMGB1) production, which is produced by macrophages and associated with aortic 
inflammation and AAA formation70. They investigated the possibility of attenuating 
HMGB1 by coculturing macrophages from mice with mesenchymal stem cells (MSCs). A 
significant increase in HMGB1 was found in macrophages treated with elastase and this 
was diminished in macrophages cocultured with MSCs. Additionally, the study showed 
the association of nicotinamide adenine dinucleotide phosphate oxidase (Nox2) and 
HMGB1 production. There was a significant decrease in HMGB1 in elastase-treated 
macrophages from Nox2-/y mice and no significant decrease in HMGB1 when treated with 
cocultured with MSCs compared to the group solely treated with elastase. This lead to the 
conclusion that Nox2 plays a role in the production of HMGB1, thus helping to form 
AAA70. 
 
1.5.2  In vivo Studies 
The most common ways to model AAA in animals involve continuous dosing of 
angiotensin II (Ang II) subcutaneously, subjecting the aorta to calcium chloride (CaCl2) 
mediated perivascular injury, or a brief perfusion of elastase to the infrarenal aorta71.  
Ang II dosing is often used to study blood pressure alterations associated with 
atherosclerosis, however Ang II has also been shown to mimic the pathophysiology of 
AAA in humans through degradation of the elastic matrix, SMC apoptosis, oxidative stress, 
 20 
and an inflammatory response72,73. The mechanism of AAA formation via Ang-II perfusion 
involves accumulation of macrophages followed by damage to elastin fibers and expansion 
of the vessel lumen with aortic remodeling and thrombus dissolution that is replaced by 
fibrous tissue and inflammatory cells74. 
Perivascular application of CaCl2 to the infrarenal aorta also mimics the 
pathophysiology associated with AAA in humans including SMC apoptosis, oxidative 
stress, and degradation of the elastic matrix75. A pitfall to the CaCl2 model are that it lacks 
aspects of human AAA pathophysiology including presence of atherosclerosis and aortic 
thrombus75. 
Of these three, elastase perfusion with porcine pancreatic elastase (PPE) is 
commonly used due to its ease of reproducibility, as the elastase is able to degrade the 
elastin fibers, subjecting the animal to AAA formation76. PPE is a serine protease that 
breaks down elastin77. It is a 240 amino acid long chain that begins with Val-16 and ends 
with Asn-245 and contains four disulfide bridges. PPE is inactive in the pancreas and is 
activated by trypsin when secreted into the intestines77. In murine animal models, the 
formation of AAA after elastase perfusion is thought to occur in two phases: the first being 
due to the loss of elastin fibers from the PPE perfusion, and the second resulting from an 
inflammatory response78. In the beginning days of this model, the elastin fibers become 
fragmented, followed by formation of a thrombus that accelerates AAA growth due to the 
activation and recruitment of MMP-2 and MMP-978. 
Nosoudi et. al investigated the possibility of pentagalloyl glucose (PGG) loaded 
nanoparticles to protect elastin and prevent the development of AAA79. Mice were treated 
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perivascularly with CaCl2 to form an aneurysm and PGG-loaded albumin nanoparticles 
were delivered through the tail vein 10 days following CaCl2 mediated injury and sacrificed 
after 38 days. The PGG-loaded nanoparticles showed fewer macrophages in the tissue, a 
reduction in MMPs, less degradation of elastin, and aided in attenuating the formation of 
AAA79,80.  
The same group conducted a study on the use of a targeted nanoparticle therapy 
conjugated with a known MMP inhibitor, doxycycline to mitigate progression of AAA 
while providing no systemic side effects81. Previous research from the group showed the 
successful development of a targeted poly(D,L-lactide) nanoparticle that was conjugated 
with an antielastin antibody in rats that were targeted to the location of the elastin 
degradation in AAA. Expansion of this research included incorporating the MMP inhibitor 
batimastat (BB-94) within the previously constructed nanoparticles as a method to target 
the specific location of AAA in rats and preventing further growth of the aneurysm. AAA 
were induced in rats using a periarterial application of CaCl2 and the drug loaded 
nanoparticles were delivered via the tail vein 10 days after AAA induction and continued 
weekly for 4 weeks. The results of the study showed that the nanoparticles successfully 
prevented MMP activity, degradation of elastin, calcification within the aorta, and 
prevention of AAA progression81. 
Studies have also been conducted to evaluate potential therapeutic treatments for 
AAA in animals by inhibiting necrosis induced by RIP3, a receptor-interacting protein 
kinase to determine if this inhibition has a significant effect on the progression of an 
established AAA82. AAA was induced in mice using elastase administration isolated within 
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the infrarenal aorta. Necrostatin-1 (Nec-1) and an optimized Nec-1, 7-Cl-O-Nec-1 (Nec-
1s), both RIP1 inhibitors (RIP1 is closely related to RIP3) were delivered to the mice 
intraperitoneally 7 days after aneurysm induction and the mice were sacrificed at day 1483. 
The results showed a significant decrease in the aortic diameter of Nec-1s treated mice 
when compared to controls, histological results that were consistent with those of normal 
mice, and an increased amount of lysyl oxidase and tropoelastin within the aorta. Together, 
these results suggest the potential for a therapeutic approach using Nec-1s that prevents 
necrosis while providing stability to established AAA through a reduction in inflammation 
and increasing connective tissue repair80,83. 
The potential use of resolvins as a potential drug therapy for AAA has also been 
investigated84. Derived from docosahexaenoic acid, D-series resolvins are associated with 
resolution of inflammation in natural processes and have shown promise in various models 
of inflammatory diseases, inhibiting proinflammatory M1 macrophages and increasing 
anti-inflammatory M2 macrophages84,85. In a study investigating AAA treatment with the 
use of RvD2 and RvD1, two D-series resolvins, AAA were induced in mice by elastase 
perfusion and treated every 3rd day with an intraperitoneal injection of these resolvins until 
sacrifice and harvest of the aorta day 14. The results showed a 25% decrease in AAA size 
at day 14 in mice that received RvD2 injections compared to control mice. Additionally, 
histology confirmed the presence of M2 macrophages in the tissue of the RvD2 mice. The 
results of this study suggest that RvD2 is a possible treatment to halt AAA progression and 
that it is protected from the inflammatory response associated with aneurysms when 
administered after aneurysm formation80,84. 
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Targeting focal adhesion kinase (FAK) has recently been studied as a potential drug 
therapy in slowing the expansion of AAA, as it has been associated with sustaining and 
intensifying inflammation associated with AAA86. After showing that FAK was necessary 
for AAA development in a CaCl2 mouse model, mice were given PF573228, a FAK 
inhibitor after CaCl2 dosage. PF573228 was either started at 3 weeks and given daily for 6 
weeks, or at 3 weeks and only given for the following 4 days. The results showed that 
targeting FAK prevents progression of AAA, prevents MMP-9 activation, and diminishes 
recruitment of macrophages80,86. 
 
1.5.3 Organ Culture Studies 
Wills, et. al exposed 1 cm sections of porcine thoracic aortas to concentrations of 
1, 10, and 100 U/mL porcine pancreatic elastase (PPE) for 24 hours prior to being placed 
in standard medium and evaluated at time points of 1, 4, 9, and 14 days87. This study 
showed the progression of elastin damage over time and MMP presence. Additionally, in 
samples cultured with autogenous leukocytes, an inflammatory response was initiated, 
furthering the destruction of elastin and increasing MMP presence. The group was able to 
develop an organ culture model of AAA by identifying the presence of specific factors 
associated with AAA, including elastin damage, MMP presence, and an inflammatory 
response87. Pitfalls of this model include the failure to provide any evidence to prove that 
the dosage of elastase did not cause cell death or any histology to show if there was cell 
migration associated with the elastase dosage. Additionally, the quantitative analysis of 
VSMC concentration did show a decrease in concentration of VSMCs present over time 
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when compared to time-matched controls, however with the lack of histology, it is 
impossible to know if this is due to cell death from the PPE or VSMC apoptosis associated 
with AAA. 
Since the publication of this paper, there has yet to be any further research in the 
development of an organ culture model of AAA. Because of this, a new organ culture 
model of progressive AAA formation is needed. This model should show elastin 
degradation and MMP presence like the Wills model, but should also show the cellular 
response to elastase dosage, providing a convincing progressive AAA model that mimics 
AAA pathophysiology in humans. 
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CHAPTER TWO 
PROJECT RATIONALE 
 
2.1 Overview 
 
Current treatments for AAA involve invasive and risky procedures after a patient 
is deemed a surgical candidate3. Additionally, progression of small AAA in most patients 
is monitored by their physician. With conflicting options on how to predict the rupture risk 
of AAA, conservative monitoring could quickly turn deadly2,3. As the progression of 
research in AAA treatment and prevention strategies increases, additional models are 
needed for researchers to use to provide proof of concept before continued studies can be 
performed in humans.  
At the moment, there has yet to be a successful organ culture model of AAA 
progression that shows the pathological features consistent with what is already known 
about AAA while maintaining cell viability87. Our lab plans to create an ex vivo organ 
culture model of AAA that minimizes cell death to fuel research for future AAA treatment 
methods.  
This research will optimize the elastase concentration and dosage time to create a 
convincing progressive AAA organ culture model in fresh porcine carotid arteries. The 
successful development of this model will be confirmed using histological assessment of 
cell migration patterns, elastin damage, VSMC concentration, cell apoptosis, and MMP-2 
and MMP-9 expression. This model will also investigate possible vascular calcification 
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associated with elastin damage. Additionally, desmosine content will be determined to 
provide further evidence of elastin damage and the relative fluorescence units (RFU) 
consistent with MMP-2 and MMP-9 presence will be used to further quantify MMP 
presence. 
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CHAPTER THREE 
MATERIALS AND METHODS 
 
3.1 Materials 
 
The following chemicals and biologics were used for the research. Carotid arteries 
from female domestic crossbred pigs with a Yorkshire background (3-4 months old, 35-45 
kg), sterile Moscona’s solution (8 g NaCl, 0.2 g KCl, 1 g NaHCO3, 1.7 g glucose, 0.005 g 
NaH2PO4 in 1 L DI water; pH 7.2), porcine pancreatic elastase (PPE) (Elastin Products 
Co., Inc., Owensville, MO), PPE buffer (100 mM Tris, 1mM CaCl2, 0.02% NaN3 in DI 
water; pH 7.8), frozen porcine carotid artery sections (Animal Technologies, Inc., Tyler, 
TX), high glucose serum free DMEM (GenDEPOT, Katy, TX), T-25 flasks (Corning 
Incorporated, Corning, NY), DMEM organ culture medium (high glucose DMEM, 10% 
FBS, 1% Penicillin/Streptomycin), 10% Neutral Buffered Formalin (Thermo Fisher 
Scientific, Waltham, MA), Tissue-TEKÒ tissue processor (Sakura Finetek USA, Inc., 
Torrance, CA), hematoxylin (Richard-Allen Scientific, San Diego, CA), permount 
mounting medium (Azer Scientific, Morgantown, PA), Motic BA210 light microscope 
(Motic, Hong Kong), Verhoeff van Gieson (VVG) staining kit (Poly Scientific R&D Corp., 
Bay Shore, NY), anti-alpha smooth muscle actin primary antibody (Novus Biologicals, 
Centennial, CO), citrate buffer (10 mM sodium citrate, 0.05% Tween 20; pH 6), goat anti 
mouse secondary antibody (Invitrogen, Rockford, IL), DAB peroxidase substrate (Vector, 
Burlingame, CA), TUNEL assay kit (Abcam, Cambridge, United Kingdom),  RUNX2 
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antibody (Santa Cruz Biotechnology, Inc., Dallas, TX), normal horse serum (Vector, 
Burlingame, CA), avidin (Vector, Burlingame, CA), biotin (Vector, Burlingame, CA), 
ABC complex (Vector, Burlingame, CA),  NovaRed peroxidase substrate (Vector, 
Burlingame, CA), OCT compound (Tissue-TekÒ, Sakura Finetek USA, Inc., Torrance, 
CA), EVOS FL wide field fluorescent microscope, DAPI (ThermoScientific, Rockford, 
IL), DQ gelatin (Life Technologies Corporation, Eugene, OR), VECTASHIELD HardSet 
Antifade Mounting Medium with DAPI (Vector, Burlingame, CA), FRET (Fluorescence 
resonance energy transfer) Substrate III (Anaspec, Inc., Fremont, CA, Pierce™ BCA 
Protein Assay (ThermoScientific, Rockford, IL), porcine desmosine ELISA kit 
(MyBioSource, San Diego, CA). 
 
3.2 Methods 
 
3.2.1 Optimizing elastase dosage 
 Initially, elastase dosage was optimized in order to determine the ideal 
concentration and dosage time to induce elastin damage, observed via Verhoeff van Gieson 
staining (described in section 3.2.4.1.2) and without obvious cell death, observed via 
Hematoxlyin and Eosin staining (described in section 3.2.4.1.1).  
Concentrations of 50U, 60U, and 80U of porcine pancreatic elastase (PPE) (Elastin 
Products Co., Inc., Owensville, MO) in PPE buffer (100 mM Tris, 1mM CaCl2, 0.02% 
NaN3 in DI water; pH 7.8) were applied to frozen carotid artery sections (Animal 
Technologies, Inc., Tyler, TX) and placed in a sterile incubator at 37°C and 5% CO2 for 10 
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minutes and then washed in high glucose serum free DMEM (GenDEPOT, Katy, TX). 
Next, the sections were placed in 10% neutral buffered formalin and processed for 
histological analysis (described in section 3.2.4.1). 
Additional optimization involved the use of concentrations of 10U and 20U of 
porcine pancreatic elastase (PPE) (Elastin Products Co., Inc., Owensville, MO) in PPE 
buffer (100 mM Tris, 1mM CaCl2, 0.02% NaN3 in DI water; pH 7.8) placed in a sterile 
incubator at 37°C and 5% CO2 for time points of 20 minutes, 40 minutes, and 60 minutes 
and then washed in high glucose serum free DMEM (GenDEPOT, Katy, TX). Next, the 
sections were placed in 10% neutral buffered formalin and processed for histological 
analysis (described in section 3.2.4.1). 
Upon histological analysis, the optimal concentration of elastase and dosage time 
was determined to be 20U of elastase for 15 minutes in a sterile incubator at 37°C and 5% 
CO2 (further described in Chapters 4 and 5). 
 
3.2.2 Obtaining fresh porcine carotid arteries 
 Following elastase optimization, fresh porcine carotid arteries were harvested from 
female domestic crossbred pigs with a Yorkshire background in Godley-Snell Research 
Center (Clemson, SC) for the following studies. All animals were 3-4 months old and 
weighed 35-45 kg. After the pigs were euthanized using commercial euthanasia solution, 
the thyroid cartilage was located. A 10 cm incision was made 3 cm laterally to the thyroid 
cartilage using a 10-blade scalpel, extending 5 cm superiorly to the thyroid cartilage and 5 
cm inferiorly to the thyroid cartilage. Curved mayo scissors were used to dissect through 
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the underlying fascia and expose the sternocephalic muscle. The sternocephalic muscle 
was retracted to expose the internal and external jugular veins, the common carotid artery, 
and the vagus nerve. The carotid sheath was dissected using a 10-blade scalpel and the 
carotid artery was isolated and removed using surgical scissors. Following excision, the 
arteries were placed in sterile Moscona’s solution (8 g NaCl, 0.2 g KCl, 1 g NaHCO3, 1.7 
g glucose, 0.005 g NaH2PO4 in 1 L DI water; pH 7.2) on ice and transported to the lab. 
 
3.2.3 Elastase dosage 
 Upon return to the lab, the fat and adventitia surrounding the arteries were removed 
using fine-tip forceps. The carotid arteries were cut to 0.75 cm long sections using a 10-
blade scalpel. Arteries were then subjected to a 20U dose of porcine pancreatic elastase 
(PPE) (Elastin Products Co., Inc., Owensville, MO) in PPE buffer (100 mM Tris, 1mM 
CaCl2, 0.02% NaN3 in DI water; pH 7.8). The artery was wrapped periarterially in sterile 
gauze absorbed with the elastase solution and placed in a sterile incubator at 37°C and 5% 
CO2 for 15 minutes. The vessels were then washed in high glucose serum free DMEM 
(GenDEPOT, Katy, TX). After the washing step, the vessels were placed in T-25 flasks 
(Corning Incorporated, Corning, NY) with 15 mL DMEM organ culture medium (high 
glucose DMEM, 10% FBS, 1% Penicillin/Streptomycin) and placed in the sterile incubator 
at 37°C and 5% CO2. The arteries were removed at 1, 3, and 7 days and placed in histology 
cassettes in 10% Neutral Buffered Formalin (Thermo Fisher Scientific, Waltham, MA). 
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3.2.4 Histology 
 Histological analysis was performed on the samples in order to investigate cell 
migration patterns, elastin fiber concentration and organization, VSMC apoptosis, MMP 
presence, and presence of calcification. Histological assessment was performed in control 
samples as well as samples that underwent elastase treatment as described previously. 
 
3.2.4.1 Paraffin Sections 
Following removal from culture, samples of 0.25 cm of tissue were put into tissue 
cassettes and fixed in 10% neutral buffered formalin for 24 hours. Following this initial 
fixation, the samples were processed in a Tissue-TEKÒ tissue processor (Sakura Finetek 
USA, Inc., Torrance, CA). Preparation of paraffin samples included immersion in formalin, 
increasing concentrations of ethanol, xylene, and finally infiltration in paraffin.  After 
processing, the samples were embedded in paraffin wax and sectioned (6 µm sections), 
stained, and cover-slipped for analysis using a light microscope. 
 
3.2.4.1.1 Hematoxylin and Eosin Staining (H&E) 
 Hematoxylin and Eosin (H&E) was performed on paraffin sections as a general 
stain to observe the extracellular matrix and the location of the cells within the tissue. The 
slides were first deparaffinized by dipping the slides in xylene for 10 dips, submerging the 
slides in xylene for 5 minutes, dipping the slides in 100% EtOH for 1 minute, submerging 
the slides in 100% EtOH for 1 minute, dipping the slides in 95% EtOH for 10 dips, 
submerging the slides in 95% EtOH for 1 minute, followed by rinsing the slides with tap 
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water until “sheeting” occurred, and then placed in distilled water for 1 minute. After 
deparaffinization, the slides were placed in hematoxylin (Richard-Allen Scientific, San 
Diego, CA) for 7 minutes and then rinsed in tap water until clear. Next, the slides were 
dipped in clarifier (Richard-Allen Scientific, San Diego, CA) 5 times, then dipped in tap 
water until a “sheeting” action occurred. The slides were then placed in bluing reagent 
(Richard-Allen Scientific, San Diego, CA) for 1 minute, placed in tap water for 1 minute, 
and dipped 10 times in 95% EtOH. The slides were then placed in eosin (Richard-Allen 
Scientific, San Diego, CA) for 35 seconds and dipped 10 times each through 2 cycles of 
95% EtOH, 2 cycles of 100% EtOH, and 2 cycles of xylene. The slides remained in xylene 
until coverslipped with permount mounting medium (Azer Scientific, Morgantown, PA). 
The slides were finally imaged using a Motic BA210 light microscope (Motic, Hong 
Kong).  
 
3.2.4.1.2 Verhoeff van Gieson Staining (VVG) 
Verhoeff van Gieson (VVG) (Poly Scientific R&D Corp., Bay Shore, NY) staining 
was performed on paraffin sections to assess the quantity and organization of the elastin 
fibers within the vessel. The slides were first deparaffinized as described above. After 
deparaffinization, the slides were placed in Verhoeff’s Working Solution, prepared as 
directed by the supplier (5 mL Hematoxylin 5% Alcoholic solution, 2 mL Ferric Chloride 
10% Aqueous, 2 mL Lugol’s Iodine Working Solution) and placed on the samples for 15 
minutes. Following this, the slides were dipped in distilled water 10 times. The slides were 
then differentiated in Ferric Chloride 2% Aqueous for 20 seconds and then rinsed in tap 
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water. Sodium Thiosulfate 5% Aqueous was then placed on the slides for 1 minute and the 
slides were then washed in tap water for 5 minutes. Next, the slides were counterstained 
with Van Gieson’s Solution for 3 minutes, rinsed with tap water briefly, allowed to dry, 
and coverslipped with permount mounting medium (Azer Scientific, Morgantown, PA). 
The slides were finally imaged using a Motic BA210 light microscope (Motic, Hong 
Kong).  
 
3.2.4.1.3 IHC for VSMCs 
IHC for detection of VSMCs was performed on paraffin sections using anti-alpha 
smooth muscle actin primary antibody (Novus Biologicals, Centennial, CO) in order to 
determine VSMC apoptosis. The slides were first deparaffinized as described above. After 
deparaffinization, the slides were heated in citrate buffer (10 mM sodium citrate, 0.05% 
Tween 20; pH 6) for 30 minutes at 95°C. The slides were then allowed to cool and were 
then washed in deionized water for 2 minutes. Following this, the slides were washed 3 
times for 2 minutes each in IHC wash buffer (0.1 M PBS, 0.05% Tween; pH 7.4). The 
slides were then blocked with 3% H2O2 for 5 minutes and washed 3 times with IHC wash 
buffer for 2 minutes each. Non-specific binding blockage was then performed with 3% 
Bovine Serum Albumin (BSA) in PBS for 10 minutes and again washed 3 times with IHC 
wash buffer for 2 minutes each. The anti-alpha smooth muscle actin primary antibody 
(Novus Biologicals, Centennial, CO) was then placed on the samples and the samples were 
allowed to incubate overnight at 4°C; 0.1% BSA in PBS was used as a negative control for 
each sample. 
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After overnight incubation, the slides were washed 3 times with IHC wash buffer 
for 2 minutes each. Following this wash, a 1:500 dilution of goat anti mouse secondary 
antibody (Invitrogen, Rockford, IL) was placed on the samples for 1 hour at room 
temperature. The slides were then washed 3 times with IHC wash buffer for 2 minutes 
each. DAB peroxidase substrate (Vector, Burlingame, CA) was then prepared according to 
the manufacturer’s directions and placed on the slides for 5 minutes followed by washing 
the slides with IHC wash buffer one time for 2 minutes. 
Following the wash, the slides were stained with hematoxylin for 30 seconds, 
dipped through a series of alcohols as described previously, and coverslipped using 
permount mounting medium (Azer Scientific, Morgantown, PA). The slides were finally 
imaged using a Motic BA210 light microscope (Motic, Hong Kong).  
 
3.2.4.1.4 TUNEL Assay 
To observe apoptotic cells, a TUNEL assay was performed (Abcam, Cambridge, 
United Kingdom). The assay was performed according to the manufacture’s 
recommendations, coverslipped using permount mounting medium (Azer Scientific, 
Morgantown, PA), and imaged using a Motic BA210 light microscope (Motic, Hong 
Kong).  
 
3.2.4.1.5 Alizarin Red Staining 
Alizarin red staining was performed to observe vascular calcification. Following 
deparrafinization as described previously, the slides were stained with 2% alizarin red 
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solution (pH 4.1-4.3) for 5 minutes. The slides were then dipped until clear in DI water and 
counterstained with 1% light green SF yellowish for 10 seconds and again dipped until 
clear in DI water. The slides were then dipped through a series of alcohols as described 
previously and coverslipped using permount mounting medium (Azer Scientific, 
Morgantown, PA). The slides were finally imaged using a Motic BA210 light microscope 
(Motic, Hong Kong).  
 
3.2.4.1.6 IHC for RUNX2 
IHC for detection of RUNX2, a transcription factor associated with osteoblast 
differentiation and one of the first markers of VSMC phenotypic switch to an osteogenic 
cell type was performed on paraffin sections using a RUNX2 antibody (Santa Cruz 
Biotechnology, Inc., Dallas, TX). The slides were first deparaffinized as described above. 
After this, the slides were boiled in citrate buffer (10 mM sodium citrate, 0.05% Tween 20; 
pH 6) for 10 minutes at 95°C. The slides were then allowed to cool. Following cooling, the 
slides were washed twice in IHC wash buffer (0.1 M PBS, 0.05% Tween; pH 7.4) for 5 
minutes each. Non-specific binding blockage with normal horse serum (Vector, 
Burlingame, CA) was then performed for 40 minutes. The slides were then washed twice 
in IHC was buffer for 5 minutes each. Avidin (Vector, Burlingame, CA) was then placed 
on the slides for 15 minutes, followed by two 5 minute washes in IHC wash buffer. Next, 
biotin (Vector, Burlingame, CA) was plated on the slides for 15 minutes, followed by two 
5 minute washes in IHC wash buffer. The RUNX2 primary antibody (Santa Cruz 
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Biotechnology, Inc., Dallas, TX) was then applied and the slides were kept overnight at 
4°C; 0.1% BSA in PBS was used as a negative control for each sample. 
Following overnight incubation, the slides were washed 2 times for 5 minutes each 
in IHC wash buffer. The slides were then blocked with 3% H2O2, for 10 minutes and then 
washed 2 times for 5 minutes each in IHC wash buffer. Following this wash, a 1:500 
dilution of goat anti mouse secondary antibody (Invitrogen, Rockford, IL) was placed on 
the samples for 1 hour at room temperature. The slides were then washed in IHC wash 
buffer twice for 5 minutes each. ABC complex was then applied (Vector, Burlingame, CA) 
for 30 minutes followed by two 5 minute washes in IHC wash buffer. NovaRed peroxidase 
substrate (Vector, Burlingame, CA) was then prepared according to the manufacturer’s 
directions and placed on the slides for 5 minutes followed by washing the slides with wash 
buffer one time for 5 minutes.  
Following the wash, the slides were stained with hematoxylin 30 seconds, dipped 
through a series of alcohols as described previously, and coverslipped using permount 
mounting medium (Azer Scientific, Morgantown, PA). The slides were finally imaged 
using a Motic BA210 light microscope (Motic, Hong Kong).  
 
3.2.4.2 Frozen Sections 
 Following removal from culture, 0.25 cm sections were cut, snap frozen in liquid 
nitrogen, and stored at -80°C until being prepared for cryosectioning. OCT compound 
(Tissue-TekÒ, Sakura Finetek USA, Inc., Torrance, CA) was placed in molds and the 
samples were positioned within the OCT compound to be sectioned axially. The molds 
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were put into a reservoir containing acetone to act as a heat transfer agent and dropped in 
liquid nitrogen to freeze. The samples were kept at -80°C and sectioned with a 
cryosectioner (ThermoScientific, Waltham, MA) (6 um sections) before being stained, 
coverslipped, and imaged for analysis with an EVOS FL wide field fluorescent microscope. 
 
3.2.4.2.1 In Situ Zymography 
 In situ zymography was performed to visualize MMP activity. Samples were air-
dried for 10 minutes and stained with 1 ug/mL DAPI (ThermoScientific, Rockford, IL) for 
2 minutes, followed by a 2 minute wash in deionized water. DQ gelatin (Life Technologies 
Corporation, Eugene, OR) was diluted 1:10 and placed in 2% (w/v) low gelling temperature 
agarose (Ambion, Inc., Foster City, CA) dissolved in deionized water. The mixture was 
placed on top of the slides and gelled at 4°C. After gelling, the slides were placed in 
development buffer (50 mM Tris Base, 5 mM CaCl2*2H2O, 200 mM NaCl, 0.02% brij 35; 
pH 7.6) overnight at 37°C. The slides were then coverslipped with VECTASHIELD 
HardSet Antifade Mounting Medium with DAPI (Vector, Burlingame, CA) and imaged 
with an EVOS FL wide field fluorescent microscope. Fluorescence of FITC (fluorescein 
isothiocyanate) was observed at an excitation of 460-500 nm and emission of 512-542 nm. 
DAPI was observed at an excitation of 340-380 nm and emission of 425-∞ nm.  
 
3.2.5 Relative Fluorescence Units (RFU) for MMPs 
 Relative fluorescence units for MMPs were determined using extracted proteins 
from the samples. Following removal from culture, samples were cut into 0.2 mm sections 
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and kept at -80°C until protein extraction. To extract proteins, the samples were cut into 
small pieces, placed in 0.5 mL RIPA buffer (50 mM Tris-HCl, 150 mM NaCl, 1% Triton 
X-100, 1% sodium deoxycholate, 0.1% SDS; pH 7.4) and homogenized with a tissue 
homogenizer (Fisher Scientific, Hampton, NH) until completely dissolved. The samples 
were then centrifuged at 10,000 rpm for 5 minutes. Following this, the supernatant was 
saved. 96 uL of substrate buffer (50 mM Tris buffer, 5 mM CaCl2, 200 mM NaCl, 0.02% 
brij-35; pH 7.5), 2 uL 360 MMP FRET (Fluorescence resonance energy transfer) Substrate 
III (Anaspec, Inc., Fremont, CA), and 2 uL of the supernatant was added to a black 96-well 
plate (Fisherbrand, Pittsburgh, PA) and read (excitation 280 nm, emission 360 nm) using 
a plate reader (BioTek, Winooski, VT).  
 A Pierce™ BCA Protein Assay (ThermoScientific, Rockford, IL) was performed. 
A solution of Reagents A and B was created according to the manufacturer’s directions, 
and 200 uL of this mixture was added to a mixture of 5 uL of supernatant and 5 uL of DI 
water in a clear 96-well plate (Fisherbrand, Pittsburgh, PA), incubated at 37°C for 20 
minutes and read at an absorbance value of 562 nM using a plate reader (BioTek, Winooski, 
VT). Known standards of varying protein concentrations were also used in order to create 
a standard curve. From the results of the BCA assay, the absorbance values from the FRET 
assay were divided by the mg protein per sample detected from the BCA assay, and the 
amount of relative fluorescence units/mg protein were able to be calculated. 
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3.2.6 Desmosine ELISA 
 The amount of desmosine in each sample was determined using a porcine 
desmosine ELISA kit (MyBioSource, San Diego, CA). Following removal from culture, 
0.2 cm sections were cut, snap frozen in liquid nitrogen, and stored at -80°C until being 
prepared for ELISA. The samples were placed in a lyphilizer (Labconco, Kansas City, MO) 
overnight and their dry weights were recorded. Following this, the samples were cut into 
small pieces and boiled in 0.5 mL 6N HCl at 95°C until dissolved. The samples were then 
dried with nitrogen gas under a laminar flow hood until the liquid was evaporated. 0.25 
mL 0.1N HCl was used to resuspend the samples. ELISA was then performed according 
to the manufacturer’s instructions. A standard curve was created with known samples and 
used to determine the amount of desmosine (ng desmosine/mg dry tissue) along with the 
recorded dry weights of the samples. 
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CHAPTER FOUR 
RESULTS 
 
4.1 Elastase Optimization 
 
 Initial attempts were made to determine how increasing concentrations of elastase 
affect elastin damage at a single time point. VVG staining showed that increasing 
concentrations (50U, 60U, and 80U) of PPE all applied for 10 minutes did not show an 
obvious change in elastin damage (Figure 4.1).  
Lower concentrations (10U and 20U) of PPE applied at increasing time points (20 
minutes, 40 minutes, and 60 minutes) showed that there was elastin damage present in the 
group treated with 20U of PPE for 60 minutes (Figure 4.2). While there was elastin damage 
seen with this dosage at days 1, 3, and 7 (Figure 4.3), H&E staining of the same samples 
revealed that there was an overwhelming amount of cell death (Figure 4.4), making a 20U 
dose for 60 minutes an unviable option for this model.  
 The use of 20U of PPE for 15 minutes was found to be the elastase dosage that 
worked to insure elastin damage, as well as minimize cell death and was the concentration 
and dosage time used for this model (Figures 4.5 and 4.6). 
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4.2 Histology 
 
4.2.1 Hematoxylin and Eosin (H&E) 
 H&E staining showed that the cells migrated from the adventitial layer of the artery, 
where the elastase was applied, towards the lumen beginning at day 1 in the elastase-treated 
group. This is not seen in any of the control groups. Of note, it appears that the cells begin 
to migrate back from the lumen to the adventitial layer of the artery at day 7. Because of 
this observation, the model was extended to include a 14 day time point, however the H&E 
staining revealed cell death in the day 14 elastase treated group (Figure 4.5). 
 
4.2.2 Verhoeff van Gieson (VVG) 
 VVG staining was performed to analyze the organization and deterioration of 
elastin fibers within the vessels. VVG staining stains elastin fibers black within the 
yellow/brown stained tissue. The elastin fibers appear numerous and organized in all 
control samples and at days 0 and 1. At day 3, the elastin fibers appear to be less thickly 
clustered and breaks are seen around the adventitial layer of the artery where the elastase 
was administered. This is also seen at day 7, with less elastin fibers located within the 
periphery of the artery than at day 3. Elastin damage is also observed in the day 14 elastase 
treated group, however since H&E staining revealed abundant cell death in this group, this 
model proceeded to evaluate samples at time points of 0, 1, 3, and 7 days (Figure 4.6). 
 
 
 42 
4.2.3 IHC anti alpha-smooth muscle actin 
 Immunohistochemistry was performed for VSMC status using the anti alpha-
smooth muscle actin antibody. There is a dramatic decrease in staining for SMC actin 
consistent with the loss of VSMCs as time progresses, particularly at day 7 (Figure 4.7). 
 
4.2.4 TUNEL Assay 
 A TUNEL assay was performed to assess the presence of apoptotic cells within the 
samples. The Terminal deoxynucleotidyl Transferase (TdT) enzyme used in the assay 
binds to the exposed 3’-OH ends of DNA present in apoptotic cells and adds biotin-labeled 
deoxynucleotides that are further labeled with a streptavidin-horseradish peroxidase 
(HRP). This complex then reacts with DAB, which stains apoptotic cells brown. The 
images showed the presence of apoptotic cells at day 7 (Figure 4.8). The presence of these 
apoptotic cells were not seen in the control sample at the same time point or any time point, 
confirming that the apoptosis was due to the elastase dosage and not due to contamination 
in organ culture.  
 
4.2.5 Alizarin Red 
 Alizarin red staining was performed to search for the presence of vascular 
calcification. The staining showed no calcification in any of the samples (Figure 4.9). 
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4.2.6 IHC RUNX2 
Immunohistochemistry was performed for RUNX2, a transcription factor 
associated with osteoblast differentiation and one of the first markers of VSMC phenotypic 
switch to an osteogenic cell type was performed using the RUNX2 antibody.  The images 
showed the presence of this transcription factor only in the day 7 elastase treated group, 
suggesting the early stages of VSMC phenotypic switch to an osteogenic cell type (Figure 
4.10). 
 
4.2.7 In situ Zymography 
 In situ zymography with DQ gelatin was performed to observe the presence and 
location of MMP-2 and MMP-9 within the samples. DQ gelatin in the gel is degraded by 
MMPs present in the tissue lysate and provides green fluorescence. DAPI stains cell nuclei 
blue.  The results of the in situ zymography showed no visible presence of MMP-2 and 
MMP-9 in the control samples used at any time point nor in the day 0 elastase treated 
group. A small amount of green fluorescence was seen in the elastase treated group at day 
1 (Figure 4.11). As time progresses, a marked increase in green fluorescence was observed 
consistent with increased MMP-2 and MMP-9 activity in the elastase treated groups at day 
3 and day 7. It appears that the green fluorescence is most intense in the elastase treated 
group at day 3, suggesting that MMP activity peaks at day 3. 
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Figure 4.1: Verhoeff van Gieson (VVG) staining showing representative images (n = 3) of 
elastin damage in porcine carotid arteries; (A) control, 10 minutes; (B) 50U elastase, 10 
minutes; (C) 60U elastase, 10 minutes; (D) 80U elastase, 10 minutes. 10x magnification. 
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Figure 4.2: Verhoeff van Gieson (VVG) staining showing representative images (n = 3) of 
elastin damage in porcine carotid arteries; (A) 20U elastase, 20 minutes; (B) 20U elastase, 
20 minutes; (C) 10U elastase, 40 minutes; (D) 20U elastase, 40 minutes; (E) 10U elastase, 
60 minutes; (F) 20U elastase, 60 minutes. Control shown in bottom left corner. 10x 
magnification. 
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Figure 4.3: Verhoeff van Gieson (VVG) staining showing representative images (n = 3) of 
elastin damage in porcine carotid arteries after a 60 minute dosage of 20U elastase; (A) 
control, day 1; (B) elastase, day 1; (C) control, day 3; (D) elastase, day 3; (E) control, day 
7; (F) elastase, day 7. 10x magnification. 
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Figure 4.4: Hematoxylin and Eosin (H&E) staining showing representative images (n = 3) 
of cell death in porcine carotid arteries after a 60 minute dosage of 20U elastase; (A) 
control, day 1; (B) elastase, day 1; (C) control, day 3; (D) elastase, day 3; (E) control, day 
7; (F) elastase, day 7. 10x magnification. 
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Figure 4.5: Hematoxylin and Eosin (H&E) staining showing representative images (n = 3) 
of cell migration patterns in porcine carotid arteries after a 15 minute dosage of 20U 
elastase; (A) control, day 0; (B) elastase, day 0; (C) control, day 1; (D) elastase, day 1; (E) 
control, day 3; (F) elastase, day 3; (G) control, day 7; (H) elastase, day 7; (I) control, day 
14; (J) elastase, day 14. 10x magnification. 
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Figure 4.6: Verhoeff van Gieson staining showing representative images (n = 3) of elastin 
damage in porcine carotid arteries after a 15 minute dosage of 20U elastase; (A) control, 
day 0; (B) elastase, day 0; (C) control, day 1; (D) elastase, day 1; (E) control, day 3; (F) 
elastase, day 3; (G) control, day 7; (H) elastase, day 7; (I) control, day 14; (J) elastase, day 
14. 10x magnification. 
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Figure 4.7: IHC for alpha smooth muscle actin showing representative images (n = 3) of 
VSMC loss in porcine carotid arteries after a 15 minute dosage of 20U elastase; (A) control, 
day 0; (B) elastase, day 0; (C) control, day 1; (D) elastase, day 1; (E) control, day 3; (F) 
elastase, day 3; (G) control, day 7; (H) elastase, day 7. 20x magnification. 
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Figure 4.8: TUNEL assay showing representative images (n = 3) of apoptosis present in 
porcine carotid arteries after a 15 minute dosage of 20U elastase; (A) control, day 0; (B) 
elastase, day 0; (C) control, day 1; (D) elastase, day 1; (E) control, day 3; (F) elastase, day 
3; (G) control, day 7; (H) elastase, day 7. 20x magnification. 
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Figure 4.9: Alizarin red staining showing representative images (n = 3) of lack of 
calcification in porcine carotid arteries after a 15 minute dosage of 20U elastase; (A) 
control, day 3; (B) elastase, day 3; (C) control, day 7; (D) elastase, day 7. 4x magnification 
(10x magnification insert). 
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Figure 4.10: IHC for RUNX2 showing representative images (n = 3) of VSMC phenotypic 
switch to an osteogenic cell type present in porcine carotid arteries after a 15 minute dosage 
of 20U elastase; (A) control, day 3; (B) elastase, day 3; (C) control, day 7; (D) elastase, 
day 7. 20x magnification. 
 
DAY 3 
DAY 7 
ELASTASE CONTROL 
A 
C 
B 
D 
 54 
 
Figure 4.11: In situ zymography showing representative images (n = 3) of MMP activity 
present in porcine carotid arteries after a 15 minute dosage of 20U elastase; (A) control, 
day 0; (B) elastase, day 0; (C) control, day 1; (D) elastase, day 1; (E) control, day 3; (F) 
elastase, day 3; (G) control, day 7; (H) elastase, day 7. 20x magnification. 
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4.3 MMP Analysis 
 
 A FRET (Fluorescence resonance energy transfer) analysis was conducted using 
the substrate specific for both MMP-2 and MMP-9, the matrix metalloproteinases 
associated with AAA. Increased RFU (relative fluorescence units) is associated with 
increased presence of these MMPs. There was a statistically significant difference (p < 
0.05) in the presence of MMPs in the elastase treated group at day 3 and day 7 when 
compared to the elastase time control at day 0 (Figure 4.12). There was also a statistically 
significant difference between the elastase treated groups at day 1 and day 3. The day 3 
elastase treated samples also showed a statistically significant difference when compared 
to the control, untreated samples at the same time point. The largest amount of activity was 
seen in the day 3 elastase treated group, followed by the day 7 elastase treated group, which 
was consistent with the in situ zymography results (Table 4.1). 
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Figure 4.12: MMP presence as represented by RFU/mg protein of tissue; (n=6: dashes 
indicate mean values, * indicates statistically significant difference (p < 0.05)). 
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Group RFU/mg protein 
Day 0 Control 32001.15 
Day 0 Elastase 34377.52 
Day 1 Control 35110.49 
Day 1 Elastase 40309.18 
Day 3 Control 38687.70 
Day 3 Elastase 51107.73 
Day 7 Control 37858.69 
Day 7 Elastase 44721.79 
 
Table 4.1: MMP presence as represented by RFU/mg protein of tissue; (n = 6) 
 
4.4 Desmosine Content 
 
 Desmosine content (ng desmosine/mg dry tissue weight) was determined using a 
porcine desmosine ELISA kit (MyBioSource, San Diego, CA). There was a statistically 
significant difference (p < 0.05) in the elastase treated group at day 0, the elastase treated 
group at day 3, and the elastase treated group at day 7. Elastase treated groups showed 
decreased desmosine content. This decrease in desmosine content showed progressive 
elastin degradation over time. Additionally, the results showed the decrease in desmosine 
content in the day 3 elastase treated groups is statistically significant (p < 0.05) when 
compared to control groups at day 1 and day 3, confirming that elastin damage is occurring 
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in the elastase treated groups relative to the control groups. The desmosine concentration 
in the control groups also decreased over time. This could be due to the continual 
degradation of ECM in organ culture. (Figure 4.13 and Table 4.2). 
 
 
Figure 4.13: Desmosine content in samples represented by ng desmosine/mg dry tissue 
weight; (n = 6; * indicates statistically significant difference (p < 0.05)). 
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Group Desmosine [ng]/dry weight tissue [mg] 
Day 0 Control 174.48 
Day 0 Elastase 174.53 
Day 1 Control 161.66 
Day 1 Elastase 150.99 
Day 3 Control 153.32 
Day 3 Elastase 111.44 
Day 7 Control 132.21 
Day 7 Elastase 110.74 
 
Table 4.2: Desmosine content in samples represented by ng desmosine/mg dry tissue 
weight; (n = 6). 
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CHAPTER FIVE 
DISCUSSION 
 
 AAA affects 1.7-12.7% of Americans and is currently the 13th leading cause of 
death in the United States3,38. Current treatments are suggested based on the risk of rupture, 
however surgical treatments remain risky and often require reintervention59. Conservative 
management of small aneurysms can also be deadly, as some research has shown that the 
risk of rupture may not be related to the size of the aneurysm. In order to further research 
into possible AAA treatments, a reliable large animal organ culture model must be 
established. The model should first optimize the concentration and dosage time of elastase 
to induce elastin damage as well as preserve cell life. Additionally, this model should show 
the progressive nature of the pathophysiology of AAA along with showing elastin damage, 
VSMC apoptosis, and presence of MMPs consistent with AAA. In order to accomplish 
this, a progressive organ culture model of AAA was investigated via elastase dosage in 
porcine carotid arteries79,80,81,82,83,84,85,86,87. 
 
5.1 Elastase Optimization 
 
 Initial attempts were made to determine how increasing concentrations of elastase 
affect elastin damage at a single time point. VVG staining showed that increasing 
concentrations (50U, 60U, and 80U) of PPE all applied for 10 minutes did not show an 
obvious change in elastin damage. From this, it was inferred that the focus should shift 
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towards evaluating how and increased dosage time would affect the elastin fibers. From 
this, lower concentrations (10U and 20U) of PPE were applied at increasing time points 
(20 minutes, 40 minutes, and 60 minutes) to determine how the length of elastase dosage 
affects elastin damage. Lower concentrations were used in the hopes of preventing 
excessive cell death that was believed would accompany higher concentrations of elastase 
for these lengthier time points. While there was elastin damage seen with a 20U dosage of 
elastase for 60 minutes, H&E staining of the same samples revealed that there was an 
overwhelming amount of cell death, making a 20U dose for 60 minutes an unviable option 
for this model.  
 The use of 20U of PPE for 15 minutes was found to be the elastase dosage that 
worked to insure elastin damage, as well as minimize cell death and was the concentration 
and dosage time used for this model. 
 
5.2 Tissue Structure 
 
5.2.1 Cell Migration 
 H&E staining showed cell migration away from the adventitial part of the artery, 
where the elastase was applied, towards the lumen beginning at day 1 in the elastase treated 
groups and is not seen in the control groups. Though the histology does show that the cells 
appear to be less abundant in these groups, the TUNEL assay revealed no apoptosis in the 
elastase treated groups, except in the day 7 group, which is consistent with VSMC 
apoptosis associated with AAA formation. This suggests that the cells are not dying, but 
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are migrating away from the adventitial dose of elastase with no remarkable effects on the 
outcome of the study or excessive cell death. There was remarkable cell death seen in the 
elastase treated group after 14 days, so the study was proceeded using time points of 0, 1, 
3, and 7 days.  
 
5.2.2 Elastin 
 Elastin fibers in the ECM are important to provide recoil for blood vessels. Elastin 
is cross-linked by lysine residues, as well as two amino acids specific to elastin, desmosine 
and isodesmosine, imparting integrity to the elastin fibers33,34. In the arteries, elastic fibers 
are organized into rings within the lumen30. Damage to elastin in AAA is due to the 
production of proteases with elastase activity by resident vascular cells within the artery, 
weakening the arterial wall, and forming AAA3.  Elastin is degraded by proteases with 
elastase activity; this can be mimicked in animal models using porcine pancreatic elastase. 
 VVG staining showed fewer elastin fibers present in the elastase treated groups at 
day 3 and day 7 compared to time-matched controls and days 0 and 1 elastase treated 
groups, suggesting a model of AAA in the day 3 and day 7 groups. This decrease in elastin 
content shown in VVG is consistent with other progressive organ culture models, showing 
a decrease in elastin fiber content over time histologically87. 
 Elastin damage can further be quantified by measuring desmosine content. As a 
cross-linking amino acid specific to elastin, a reduction in desmosine content within the 
tissue suggests elastin damage within the ECM. We were able to show a significant 
reduction in desmosine content in the day 3 elastase group (111.44 ng desmosine/mg dry 
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tissue weight) and the day 7 elastase group (110.74 ng desmosine/mg dry tissue weight) 
compared to the day 0 elastase group (174.53 ng desmosine/mg dry tissue weight), showing 
the progressive nature of this model in lowering the amount of desmosine in the tissue over 
time. Additionally, there was a statistically significant difference in the day 3 control and 
day 3 elastase treated groups (153.32 ng desmosine/mg dry tissue weight vs. 111.44 ng 
desmosine/mg dry tissue weight), suggesting significant elastin damage that could be 
consistent with AAA formation.  
Of note, the weight of desmosine in the control samples did seem to decrease 
slightly over time. It is important to note that even though there was a decrease over time 
in the amount of desmosine present in the control groups, none of these decreases were 
statistically significant. This suggests that there could be some level of degradation of ECM 
in the organ culture.  
 
5.2.3 VSMC Apoptosis 
Diminished presence of VSMCs are thought to have implications in repair of the 
ECM during AAA formation, as they have roles in matrix synthesis, recruitment of 
inflammatory cells, and controlling proteases 50,51,52,53,55. VSMCs are also associated with 
MMP-9 synthesis, increasing the amount of MMP-9 activation in AAA55. VSMC apoptosis 
is thought to be associated with degradation of the tunica media in this pathological 
process88.  
Our organ culture model showed a significant decrease in VSMC in the day 7 
elastase treated group. This is shown histologically in IHC staining for alpha smooth 
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muscle actin and in the TUNEL assay, showing cell apoptosis in the day 7 elastase treated 
group that was not seen in time-matched controls.  
The presence of diminished VSMCs in the tissue shown in IHC staining along with 
apoptosis present in the TUNEL assay is consistent with previous studies in AAA 
formation, suggesting that this marker consistent with AAA formation is present in this 
model89,90. 
 
5.2.4 Vascular Calcifiation 
VSMC apoptosis is also associated with vascular calcification, as apoptotic blebs 
form and are able to collect calcium in a crystalized form56. Staining for calcification via 
Alizarin red showed no calcification in the day 3 and day 7 samples, however IHC staining 
for RUNX2, a transcription factor associated with osteoblast differentiation and one of the 
first markers of VSMC phenotypic switch to an osteogenic cell type was shown in the day 
7 elastase treated group. This positive result suggests that the VSMCs in the day 7 elastase 
treated group are undergoing a phenotypic switch to an osteogenic cell type.  
 
5.2.5 MMP Presence 
The presence of MMP-2 and MMP-9 is frequently associated with AAA, as they 
are both implicated in the degradation of collagen and elastin51,53. MMP-2 and MMP-9 are 
both secreted by resident VSMCs.  
The results of in situ zymography for MMP-2 and MMP-9 show the presence of 
MMP-2 and MMP-9 in the day 3 and day 7 elastase treated groups when compared to time 
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matched controls, consistent with the pathophysiology associated with AAA. Additionally, 
the increase in the presence of MMP-2 and MMP-9 is not seen in the day 0 and day 1 
elastase treated groups, suggesting the progressive nature of this model, as the proteases 
become active in the later time points. The in situ zymography results showing 
fluorescence due to MMP presence are consistent with previous in situ zymography results 
published in AAA animal models81. 
In order to provide additional quantitative evidence of MMP presence in the 
samples, a FRET analysis was conducted. Consistent with the in situ zymography, a 
significant increase in MMP presence was seen in the day 3 (51107.73 RFU/mg protein) 
and day 7 (44721.79 RFU/mg protein) elastase treated groups when compared to the 
elastase treated group at day 0 (34377.52 RFU/mg protein). 
There was little variation and no statistically significant difference in any of the 
control groups, suggesting consistency in the lack of MMP production in control samples. 
Though the day 7 elastase samples showed a decreased presence of MMP when compared 
to the day 3 elastase samples, there was no significant difference in the day 7 elastase group 
and time matched control, while there was a significant difference in the day 3 samples 
compared to the time matched control.  
 The decrease in MMP presence from day 3 to day 7 can be contributed to VSMC 
apoptosis. IHC for alpha smooth muscle actin and the TUNEL assay showed significant 
apoptosis of VSMC in the day 7 elastase group compared to the day 3 elastase group. Since 
VSMCs secrete MMPs, the apoptosis of VSMCs in day 7 accounts for the decrease in 
MMP presence seen in the in situ zymography and the FRET analysis.  
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5.3 Mechanism of Progressive Elastin Damage 
 
Porcine pancreatic elastase (PPE) serine protease that was used to break down 
elastin77. PPE is inactive in the pancreas and is activated by trypsin when secreted into the 
intestines77. Elastin damage initiating aneurysm formation in animals in induced first by 
the loss of elastin fibers from the PPE perfusion, followed by continued damage due to an 
inflammatory response78. In the beginning days of this model, the elastin fibers become 
fragmented, followed by formation of a thrombus that accelerates AAA growth due to the 
activation and recruitment of MMP-2 and MMP-978.  
Because this model was not an in vivo model, the typical extent of an inflammatory 
response did not occur. The progressive nature of this model is a result of the formation of 
elastin peptides formed during elastin fiber damage initiated by elastase, producing elastin 
peptides that act on the elastin-laminin receptor on the resident VSMCs, causing these 
VSMCs to become more inflammatory and furthering vessel damage and AAA 
pathogenesis91,92. 
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CHAPTER SIX 
CONCLUSIONS AND RECOMMENDATIONS 
 
6.1 Conclusions 
 
AAA is currently the 13th cause of death in the United States. Current surgical 
treatments for AAA are risky and invasive. Additionally, conservative measures can 
become deadly due to the dissenting information regarding AAA rupture mechanisms. 
Research into alternative treatment methods is abundant, particularly in small animal 
models, however there lacks a suitable organ culture model to replicate AAA for research 
to continue. 
 The results of this study show a promising organ culture model of AAA to fit this 
need. Elastase was used to degrade elastin fibers initiating the development of AAA. The 
progressive nature of this model is a result of the elastase-induced release of elastin 
peptides from elastin fibers91. These elastin fibers were then able to interact with the 67 
kDa elastin-laminin receptor on the resident VSMCs, causing these cells to become more 
inflammatory and further the pathogenesis of AAA92. This study showed elastin 
degradation histologically, as well as through a decrease in desmosine content to provide 
evidence of elastin degradation consistent with AAA. Additionally, the decrease in VSMC 
concentration and prevalence of VSMC apoptosis in the day 7 elastase treated group shown 
are also present in AAA pathophysiology. While this VSMC apoptosis at day 7 does not 
show any associated calcification at that time point, histology does show the presence of 
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transcription factors associated with VSMC phenotypic switch to a more osteogenic cell 
type. Additionally, analysis of MMPs showed their presence in the day 3 and day 7 elastase 
treated group providing further evidence of a successful model of AAA. The slight 
decrease in MMP presence in the day 7 elastase treated group compared to the day 3 
elastase treated group is due to the VSMC apoptosis shown in the day 7 elastase treated 
group, as VSMCs are responsible for MMP production; therefore, a reduction in VSMCs 
results in a reduction in MMPs. Lastly, the elastase dosage was optimized to prevent 
excessive cell death to recapitulate an in vivo response. 
 While the day 3 and day 7 elastase treated groups both showed markers consistent 
with AAA, the day 7 group shows additional promise in further research due to possible 
VSMC phenotypic switches that should be further investigated. 
 Thus, we have successfully shown a progressive model of AAA formation. This 
model provides evidence of important pathological markers present in AAA including 
elastin degradation, VSMC apoptosis, and MMP production. 
 
6.2 Limitations 
 
 Despite the success of this model previously described, there are limitations to be 
considered. Because this model is performed ex vivo, the inflammatory response associated 
with AAA was unable to be replicated in this model as it would occur in an in vivo model. 
Additionally, this model was performed in static culture and did not replicate blood flow 
through the vessels as it would occur in the human body. 
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6.3 Recommendations 
 
 This study has demonstrated a successful organ culture model of AAA formation 
by characterizing basic pathological responses consistent with AAA. Future work should 
include long term studies to investigate the VSMC phenotypic switches. Experiments 
should be performed to determine if there is an increase in BMP or alkaline phosphatase 
and formation of calcium deposits. This will provide additional insight to the relationship 
between vascular calcification and AAA. 
 Additionally, performing this study in perfusion culture could provide valuable 
insight into how fluid flow affects the results of this study, as perfusion culture would more 
mimic blood flow through the arteries in humans. Furthermore, as high blood pressure is 
strongly associated with AAA, perfusion culture would also allow the ability for the vessel 
to be pressurized in order to mimic the conditions of those with hypertension. From this, 
the effects of high blood pressure could be established. 
 As mentioned previously, a limitation to this model is its inability to fully capture 
the inflammatory response associated with AAA as it would occur in an in vivo model. 
Incorporating inflammatory cells like macrophages and cytokines associated with this 
response would provide a more realistic model of this disease. 
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